This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.

开始日期2025-12-01

申办/合作机构

The University of Alabama at Birmingham

NCT06632483

/ Not yet recruitingN/A

Retrospective, Non-interventional Database Study for the Evaluation of Real-world Drug Use Patterns, Clinical Characteristics and Clinical Outcomes in Patients Initiated on Vericiguat in India

This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and even death.
The study drug, vericiguat, is already approved for doctors to prescribe to people with worsening of heart failure with chronic HFrEF in India.
Vericiguat increases the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels, allowing more blood to flow through. As a result, the heart is able to pump better.
The participants in this study are already receiving treatment with vericiguat as part of their regular care from their doctors. There is currently limited real-world data on the use of vericiguat. Furthermore, discussing whether vericiguat treatment should start early in people with heart failure can help doctors manage these people better.
The main purpose of this study is to collect information about how well vericiguat works and how safe it is in Indian people with chronic HFrEF who have experienced worsening heart failure. To do this, researchers will collect the following information:
* participants' characteristics, including age, sex, height, weight, and medical history
* additional medicines participants have taken with vericiguat
* other treatment options participants have taken for the treatment of heart failure
* levels of NT-pro BNP* in participants' blood at least one month before taking vericiguat (*NT-proBNP is made by heart muscles. People with heart diseases have increased levels of NT-proBNP in their blood. Measuring NT-proBNP levels in the blood can help doctors identify heart disease.)
* number of participants from India, divided into four zones-North, South, East, and West
* categorization of participants based on how heart failure limits physical activity and classification of heart failure by cause
* change in heart function measured by how much blood the left side of the heart can pump out
* number of hospitalizations and number of participants who died due to heart-related and non-heart-related events
* number of participants who experienced low blood pressure or fainting after starting treatment with vericiguat
* participants who discontinued treatment with vericiguat, due to low blood pressure or fainting
The data will come from the participants' hospital, medical and electronic healthcare records. Data collected will be from Indian people with chronic HFrEF who started taking vericiguat between September 2022 and August 2023.
Researchers will track participants' data and will follow them until Feb 2024. In this study, only available data from routine care are collected. No visits or tests are required as part of this study.

开始日期2025-10-01

申办/合作机构

Bayer AG

ChiCTR2500109953

/ Not yet recruitingN/AIIT

A prospective multicenter clinical trial of targeted anti-inflammatory and anti-fibrotic therapy in patients with type 2 diabetes and concomitant cardiorenal disease

开始日期2025-10-01

申办/合作机构

郑州大学第一附属医院

[+1]

100 项与维立西呱相关的临床结果

登录后查看更多信息

100 项与维立西呱相关的转化医学

登录后查看更多信息

100 项与维立西呱相关的专利（医药）

登录后查看更多信息

351

项与维立西呱相关的文献（医药）

2025-12-01·BIOCHEMICAL PHARMACOLOGY

Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure

Review

作者: Melenovský, Vojtěch ; Gawrys, Olga ; Kala, Petr ; Šnorek, Michal ; Corda, Stefano ; Sandner, Peter

Heart failure (HF) is a life-threatening disease characterized by substantial morbidity and mortality. Yet despite recent advances, prognosis remains poor. Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide range of physiological processes in various cell types. Its deficiency has been implicated in numerous pathological cardiovascular diseases, including HF, pulmonary hypertension (PH), and kidney disease. Therefore, restoring and enhancing the nitric oxide (NO)-soluble guanylyl cyclase (sGC)-cGMP signalling pathway appears to have far-reaching therapeutic potential. The discovery of sGC stimulators and activators marked a milestone in the field of NO-sGC-cGMP pharmacology, enabling NO-independent and long-acting enhancement of cGMP signalling without the formation of NO-derived radicals. Over a decade ago, the sGC stimulator riociguat was approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH). More recently, the sGC stimulator vericiguat was approved for symptomatic chronic HF. A number of sGC activators are currently being investigated for the treatment of chronic kidney diseases. This review summarizes the evidence for NO-sGC-cGMP signalling in the regulation of cardiovascular and cardiac function, focusing on preclinical and clinical evidence for sGC stimulators and sGC activators in HF subtypes. Promising results have been observed in clinical trials of HF with reduced ejection fraction (HFrEF), but not in clinical trials of HF with preserved ejection fraction (HFpEF). Further studies are needed to determine the precise mechanisms of action of sGC agonists in HF and associated cardiorenal diseases to fully leverage their therapeutic potential and address the challenges of implementing these agents in routine clinical practice.

2025-11-01·American Journal of Rhinology & Allergy

Vericiguat Enhances Olfactory Function in Post-Infectious Anosmia: A Randomized Pilot Double-Blind Placebo-Controlled Trial

Article

作者: Alharbi, Adnan ; Baali, Fahad H. ; Altemani, Abdullah H. ; Abdelazim, Ahmed H. ; Algarni, Majed A. ; Abdelazim, Mohamed H. ; Alzarea, Abdulaziz Ibrahim ; Alshammari, Abdullah S.

Background:

Olfactory dysfunction affects approximately 29% of the population and has a profound impact on quality of life. It frequently follows upper respiratory tract infections and lacks effective pharmacological treatments. Vericiguat, a soluble guanylate cyclase stimulator that increases intracellular cyclic guanosine monophosphate, is approved for heart failure and has potential neuro-modulatory effects relevant to olfactory processing.

Objective:

This pilot study investigates the efficacy of oral vericiguat in improving olfactory function in patients with persistent anosmia following upper respiratory tract infections.

Methods:

In a double-blind, randomized controlled trial, 88 participants with post-infectious anosmia were assigned to receive either placebo (n = 44) or vericiguat (4 mg, twice daily; n = 44) for 12 months. Olfactory function was assessed monthly using the Sniffin’ Sticks test, measuring Threshold (T), Discrimination (D), and Identification (I) scores. Data were analyzed using repeated-measures ANOVA and post-hoc Bonferroni corrections.

Results:

At baseline, all olfactory scores were similar between groups. In the vericiguat group, T scores increased from 3.84 ± 0.19 to 4.65 ± 0.20 (P = 0.003), D scores from 8.25 ± 0.65 to 9.20 ± 0.86 (P = 0.008), and I scores from 7.34 ± 0.72 to 8.62 ± 0.79 (P = 0.008). No significant changes were observed in the placebo group. Between-group differences became statistically significant for D at month 4 (P < 0.05), T at month 6 (P < 0.05), and I at month 7 (P < 0.05). However, the mean total TDI improvement in the vericiguat group (+ 3.19) did not reach the clinical threshold of 5.5 points.

Conclusion:

Vericiguat significantly improved olfactory threshold, discrimination, and identification scores compared to placebo. These findings highlight its potential as a pharmacological option for olfactory dysfunction, although the clinical magnitude of benefit remains below the established threshold. Further studies should explore mechanisms and broader clinical applications.

Trial registration:

DFM-IRB00012367–23-07-008.

2025-11-01·CURRENT CARDIOLOGY REVIEWS

Vericiguat: A Promising Drug for the Treatment of Heart Failure

Article

作者: Patel, Ashish ; Patel, Bhavesh ; Patel, Dharti ; Patel, Alkesh ; Shah, Drashti

The health and survival of people with heart failure is a growing concern due to the associated illness and death. Traditional treatments such as medication, surgery, and lifestyle changes have not significantly improved life expectancy, leading to a search for more effective drug options. A drug that can act on oxidative stress and cardiac inflammatory markers while carrying the benefits of existing therapies is needed. Targeting the soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) dependent pathway significantly reduces cardiac myocyte death and improves ejection fraction. In 2021, the USFDA approved Vericiguat, a derivative of pyrazolo [3,4-b]pyridine, to decrease the risk of cardiovascular death and hospitalization. This review provides information on the structure, pharmacokinetics, pharmacodynamics, clinical status, and treatment of Vericiguat in heart failure. Riociguat was the first sGC stimulator used in pulmonary hypertension therapy, but its short half-life required multiple dosing, making it unsuitable for cardiovascular diseases. Vericiguat was developed to address this limitation by decreasing metabolism, and both preclinical and clinical investigations have indicated its minimal pharmacokinetic interactions. This makes it appropriate for long-term use in cardiac patients with multiple comorbidities who require several medications. Vericiguat represents a promising new option for heart failure treatment, potentially improving patient outcomes and quality of life. Its compatibility with other heart failure therapies without significant drug-drug interactions further highlights its potential as a cornerstone treatment. Ongoing studies continue to explore its benefits, suggesting that vericiguat may enable more comprehensive and effective management of heart failure, reducing the burden of this debilitating condition.

项与维立西呱相关的新闻（医药）

2025-09-04

·PRNewswire

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 26-29

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN. Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Continue Reading Heart Failure Society of America Annual Scientific Meeting 2025 takes place September 26-29 in Minneapolis, MN. Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 1: Devices and Cardiomyopathies Integra-D Trial Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial FUTURE-HF Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio DETECT-HF Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days FOREST-HCM Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: a 96-week analysis from FOREST-HCM MAPLE-HCM Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM ATTRibute-CM Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM HELIOS-B Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 2: Novel Therapies VICTOR Trial Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients with HFrEF Enrolled in the VICTOR trial Tolerability and Safety of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction SEISMiC C Safety and Efficacy of Intravenous Administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to Acute Heart Failure SUMMIT Trial Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial GARDEN TIMI-74 GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial Danicamtiv Trial Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network First-In-Human Implantation of a Next-Generation Membrane-Based LVAD Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis Screening for advanced heart failure in stable outpatients (The SAINTS study) Sunday, September 28 | Rapid Fire 2: | 2:15 PM - 3:15 PM Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial Expanded Results from a Guideline-Directed Medical Therapy Clinic Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset PROACTIVE-HF: 2-year outcomes, stratified by LVEF Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2025. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected] SOURCE Heart Failure Society of America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期临床1期

2025-09-02

·FiercePharma

Merck, Bayer's Verquvo posts perplexing trial fail in patients with stable HFrEF

Analysts don't hold big expectations for Verquvo because of competition in the heart failure field. Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF).The phase 3 Victor trial failed on its primary endpoint, as Verquvo didn’t beat placebo in terms of combined time to first heart failure hospitalization or cardiovascular death, according to results presented at the European Society of Cardiology Congress 2025. The study evaluated Verquvo in more than 6,100 well-managed HFrEF patients who had not had a heart failure hospitalization within six months or the need for outpatient intravenous diuretics within three months prior to the study. About 47.5% of patients had no history of hospitalization for heart failure.The readout was perplexing because investigators observed seemingly divergent results on the two components that formed the trial’s primary composite endpoint.Verquvo led to a numerical 17% reduction in the risk of heart-related death. The number did not bear statistical significance because secondary endpoints were not formally tested thanks to the trial’s failure on its primary endpoint.Death from cardiovascular causes occurred in 292 (9.6%) patients in the Verquvo arm and 346 (11.3%) in the control group after a median follow-up of 19.7 months, according to results simultaneously published in The Lancet.In contrast, the drug showed no sign of benefit on time to first heart failure hospitalization, with Verquvor’s 11.4% first-time hospitalization rate during the study timeframe looking similar to placebo’s 11.9%. When first and recurrent hospitalizations were counted, Verquvo’s rate was 10.7 events per 100 patient-years versus 11.8 events per 100 patient-years for the placebo cohort.“Cardiovascular death is a clinically meaningful and less ambiguous endpoint than outcomes such as hospitalization, which can be influenced by clinical practice and regional variation,” the Victor trial’s investigators wrote in The Lancet paper.Trying to reconcile the difference between the two endpoints, the researchers pointed to “the unprecedented high use of guideline-directed medical therapy,” such as SGLT2 inhibitors, in a population with overall low risk at baseline. Even though the researchers hypothesized that the high use of contemporary therapy and low recent hospitalization rates could offer plausible explanations for the lack of a hospitalization benefit, they acknowledged that “[t]he reason for the observed mortality benefit in the absence of a reduction in heart failure hospitalization is unclear.”All told, on the composite endpoint, Verquvo only led to a nonsignificant 7% reduction in the risk of cardiovascular death or first hospitalization for heart failure during a median follow-up of 18.5 months.Verquvo received its initial FDA approval in HFrEF in 2021 based on results from the phase 3 Victoria trial. The study linked the soluble guanylate cyclase stimulator to a reduced risk of cardiovascular death and heart failure hospitalization versus placebo among patients with worsening disease. At ESC, Merck also trotted out a pooled analysis of Victor and Victoria, showing that Verquvo significantly reduced patients’ risk of cardiovascular mortality or heart failure hospitalization by 9% versus placebo. The risk reduction was 11% and 8% for the marker’s two components, respectively.Through a collaboration formed in 2014, Merck markets Verquvo in the U.S. and Bayer commercializes it in the rest of the world.Analysts don't hold big expectations for Verquvo because of competition in the heart failure field. At the time of the drug’s approval in 2021, Leerink Partners analysts projected its U.S. peak sales would reach $300 million based on some use in HFrEF patients who are not optimally managed on Novartis’ Entresto.In the first half of 2025, Merck only recorded $21 million in sales from the med in the U.S.

临床3期上市批准临床结果AHA会议

2025-09-02

·EndPoints

Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager

Plus, news about Zenas BioPharma, OMass Therapeutics, Merck, Bayer, Convalife Pharmaceuticals, Mabwell Bioscience, CapVest, Stada and vTv Therapeutics: 💰 Servier licenses Ideaya Biosciences’ cancer drug: The French pharma is getting the ex-US rights to Ideaya’s experimental uveal melanoma drug for $200 million upfront. Servier could fork over another $320 million in biobucks for the Phase 2/3 candidate, which is named darovasertib. — Kyle LaHucik 🧪 Zymeworks discontinues work on T cell engager: The biotech determined that its additional dose evaluation in a Phase 1 trial of ZW171 wouldn’t yield the benefit-risk profile it wanted. Zymeworks had planned to test the TCE in cancers with high levels of mesothelin. — Jaimy Lee 🧾 Zenas BioPharma makes a royalty deal: Royalty Pharma is paying $75 million upfront and up to $300 million total in exchange for the royalties on sales of obexelimab, Zenas’ experimental bifunctional monoclonal antibody that’s being tested in several autoimmune diseases. An increasing number of biotechs are inking royalty deals to bolster their balance sheets. — Jaimy Lee 🇨🇭 OMass Therapeutics, Roche ink deal: The Swiss drugmaker is paying $20 million upfront for the rights to develop and commercialize OMass’ preclinical oral inflammatory bowel disease program. There are also more than $400 million in milestones and tiered royalties on the table. — Jaimy Lee 🫀 Merck and Bayer’s Verquvo fails a Phase 3 study in heart failure: The companies have been testing the drug in adults with stable chronic heart failure and reduced ejection fraction. Verquvo is already approved to treat a different subset of patients with heart failure. — Jaimy Lee 🇨🇳 Two Chinese biotechs file for IPOs in Hong Kong: This includes Convalife Pharmaceuticals , a decade-old cancer drug developer with one approved medicine and 16 others in development, and Mabwell Bioscience , a cancer and age-related diseases biotech founded eight years ago. Mabwell is already listed on the Shanghai Stock Exchange STAR Market. It tried for an HKEX listing in January but let its filing lapse. The companies are the latest to file to go public in the still active IPO market in Hong Kong. — Kyle LaHucik 🇩🇪 CapVest Partners takes a majority stake in Stada: Sources told The Financial Times that Stada has a valuation of roughly €10 billion, including debt. Bain Capital and Cinven acquired Stada in 2017 and then took the German pharma company private. Stada was known as a generics maker but has since broadened its business into consumer healthcare and specialty drugs. The deal is expected to close in the first half of next year — Jaimy Lee 💊 vTv Therapeutics’ $80M private placement: The company plans to use the funding to advance cadisegliatin, its Phase 3 adjunctive therapy to insulin for patients with type 1 diabetes. The PIPE’s investors include several institutional investors and the T1D Fund. — Jaimy Lee

临床1期并购上市批准临床3期引进/卖出

100 项与维立西呱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11051	维立西呱	C01DX	DB15456

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
射血分数降低的慢性心力衰竭	中国	Bayer AG	2022-05-18
慢性心力衰竭	欧盟	Bayer AG	2021-07-16
慢性心力衰竭	冰岛	Bayer AG	2021-07-16
慢性心力衰竭	列支敦士登	Bayer AG	2021-07-16
慢性心力衰竭	挪威	Bayer AG	2021-07-16
心脏衰竭	美国	Merck Sharp & Dohme LLC	2021-01-19
休克	美国	Merck Sharp & Dohme LLC	2021-01-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
左心室收缩功能障碍	临床3期	巴西	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	加拿大	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	丹麦	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	法国	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	德国	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	意大利	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	荷兰	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	韩国	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	西班牙	Merck Sharp & Dohme LLC	2023-05-31
左心室收缩功能障碍	临床3期	瑞典	Merck Sharp & Dohme LLC	2023-05-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06195930 (VELOCITY, CTgov)	临床2期	射血分数降低的慢性心力衰竭 \| 慢性心力衰竭	106	Vericiguat	窪選簾顧夢糧鏇醖壓餘 = 醖觸網遞獵蓋衊簾鬱衊簾膚窪夢壓選鹽壓膚選 (簾鬱膚壓艱鬱鹹鹹觸淵, 選繭繭鹹壓蓋淵鬱網衊 ~ 蓋網選觸襯壓構夢淵構) 更多	-	2025-09-25
NCT05093933 (VICTOR, Company_Website \| Lancet) 人工标引	临床3期	射血分数降低的心力衰竭	6,105	Vericiguat	醖憲憲淵淵醖鏇廠淵窪(淵構衊廠範襯艱廠憲餘) = 夢願顧築範淵鏇願築製網艱憲齋夢廠醖範膚積 (糧選憲遞衊醖範積簾夢 ) 更多	不佳	2025-08-29
NCT05093933 (VICTOR, Company_Website \| Lancet) 人工标引	临床3期	射血分数降低的心力衰竭	6,105	placebo	醖憲憲淵淵醖鏇廠淵窪(淵構衊廠範襯艱廠憲餘) = 鬱繭遞繭艱範鹹餘簾積網艱憲齋夢廠醖範膚積 (糧選憲遞衊醖範積簾夢 ) 更多	不佳	2025-08-29
NCT02861534 (VICTORIA, Pubmed \| J Card Fail)	临床3期	心脏衰竭 GDF-15 \| NT-proBNP \| albumin ... 更多	373	Vericiguat	餘獵蓋選鹹觸衊齋鏇廠(鑰繭繭艱願鬱淵憲鑰顧): HR = 0.85 (95.0% CI, 0.77 ~ 0.94) 更多	积极	2025-08-01
NCT02861534 (VICTORIA, Pubmed \| J Card Fail)	临床3期	心脏衰竭 GDF-15 \| NT-proBNP \| albumin ... 更多	373	Placebo		积极	2025-08-01
VELOCITY (NEWS) 人工标引	临床2期	射血分数中等的心力衰竭	106	维立西呱 5mg	齋壓鑰餘壓窪積夢獵餘(簾衊選廠夢艱襯構築範) = 製獵鏇範繭餘壓積顧觸膚築鹽簾糧製鏇夢廠襯 (鑰構鬱糧構鹽簾壓蓋醖 ) 达到	积极	2025-05-20
NCT06195930 (VELOCITY, Pubmed \| Eur J Heart Fail)	临床2期	心脏衰竭	106	Vericiguat 5 mg	襯製鹹齋廠醖構築鹹衊(觸遞夢窪壓襯糧願簾築) = 壓選選夢願選積觸觸構積顧積鹽襯鬱網繭醖繭 (網獵獵窪繭鬱齋顧製醖 )	积极	2025-05-19
ESC2024	N/A	心脏衰竭	-	Vericiguat	壓餘衊憲積鹽壓艱網鏇(鏇網顧觸鏇鹽構繭齋醖) = 積糧鑰繭醖構積齋蓋憲選襯壓齋選築獵醖衊醖 (淵廠餘鹽膚艱夢製遞顧, 1.05)	-	2024-05-13
ESC2024	N/A	-	-	vericiguat (VERITA registry)	鬱鏇齋膚鹹壓鬱衊鹹夢(餘廠觸積構願艱範遞積) = 蓋繭獵築網餘繭觸繭鹹選鏇齋餘鬱獵夢鏇齋衊 (顧顧築網襯糧齋顧襯鏇 )	-	2024-05-12
ESC2024	N/A	-	-	vericiguat (VICTORIA trial)	鬱鏇齋膚鹹壓鬱衊鹹夢(餘廠觸積構願艱範遞積) = 遞醖廠鬱繭淵淵鹽積醖選鏇齋餘鬱獵夢鏇齋衊 (顧顧築網襯糧齋顧襯鏇 )	-	2024-05-12
ESC2024	N/A	-	-	vericiguat (Women)	選鹹餘製鏇顧膚廠窪獵(衊積範鏇醖鏇艱簾窪構) = 壓觸窪網鏇蓋願遞構憲餘鹹獵夢醖遞構艱鹽鏇 (願齋鑰鹹構糧蓋齋製憲 ) 更多	-	2024-05-12
ESC2024	N/A	-	-	vericiguat (Men)	選鹹餘製鏇顧膚廠窪獵(衊積範鏇醖鏇艱簾窪構) = 遞選廠糧製鹹顧繭憲範餘鹹獵夢醖遞構艱鹽鏇 (願齋鑰鹹構糧蓋齋製憲 ) 更多	-	2024-05-12
NCT02861534 (VICTORIA, ESC2024)	临床3期	心脏衰竭 NTproBNP	200	Vericiguat	齋製膚醖壓繭鑰淵衊餘(網膚蓋繭網淵襯憲範窪) = 蓋鬱鏇餘築鬱蓋醖淵製糧糧窪廠糧艱網選獵壓 (構艱鹽壓鹽衊選觸壓窪 )	积极	2024-05-12
NCT02861534 (VICTORIA, Pubmed \| JACC Heart Fail) 人工标引	临床3期	心脏衰竭 \| 射血分数降低的心力衰竭 N-terminal pro-B-type natriuretic peptide levels	4,050	Vericiguat	選齋鬱鏇範醖蓋憲襯衊(糧鹽壓壓簾網鏇淵襯鬱) = 膚艱壓齋齋廠餘鏇憲糧淵憲衊鹹網鏇壓餘淵餘 (夢網顧襯壓憲選鹽齋淵 )	不佳	2024-01-22